Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fremanezumab - Teva Pharmaceutical

Drug Profile

Fremanezumab - Teva Pharmaceutical

Alternative Names: AJOVY; Anti-calcitonin gene-related peptide monoclonal antibody; Anti-CGRP monoclonal antibody; fremanezumab-vfrm; LBR-101; PF-04427429; PF-4427429; RN-307; TEV-48125

Latest Information Update: 31 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rinat Neuroscience
  • Developer Rinat Neuroscience; Teva Pharmaceutical Industries
  • Class Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Migraine
  • Phase II Fibromyalgia; Headache
  • Discontinued Cluster headache

Most Recent Events

  • 31 Oct 2019 Efficacy data from a two phase III trial in Migraine presented at the 71st Annual Meeting of the American Academy of Neurology (AAN-2019)
  • 22 Aug 2019 Adverse events and efficacy data from the phase III FOCUS trial in Migraine released by Teva Pharmaceutical
  • 25 Jul 2019 Teva Pharmaceutical initiates a phase I trial for Migraine (Prevention, In children) (SC) in USA (EudraCT2018-000734-35)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top